Our NanoDDS can increase the low response rate of ICB for GBM through increased co-encapsulation and specific activation of ICB antibodies and chemotherapeutic agents, as evidenced by the therapy of A2-APM to potently eradicate GBM in preclinical models. Here, ANPEP is linked to glioblastoma.